Dr. Brian Druker, director of the Knight Cancer Institute at Oregon Health & Science University, championed the drug that became Gleevec.

When the Food and Drug Administration approved Gleevec to treat a form of leukemia in 2001, it ushered in a new era in cancer care.

(Image credit: Kristyna Wentz-Graff)